14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SIGA vs IRWD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas IRWD carries 37.5/100 (SELL) at $4.71 (12.3x Forward P/E, 62.9% operating margin).
Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. IRWD 37.5/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.2% operating margin) and revenue trajectory (+9.0% vs. -49.7% YoY).
Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($20M)
90D Engineering Disclosures0 Published
IRWD Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $791.3M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($54M)
90D Engineering Disclosures0 Published
Investor FAQ SIGA vs IRWD Key Questions & Quantitative Answers
As of Nov 19, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas IRWD carries 37.5/100 (SELL) at $4.71 (12.3x Forward P/E, 62.9% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. IRWD 37.5/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.2% operating margin) and revenue trajectory (+9.0% vs. -49.7% YoY). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 65.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IRWD leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with IRWD at +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while IRWD shifted -14.3%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($54M) (0 disclosures) for IRWD.
SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas IRWD trades at 12.3x Forward P/E, 5.3x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus IRWD (-574.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, IRWD carries 73.8% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.